Skip to main content
  • English
  • Français
  • Español
  • Russian

Breadcrumb

  1. Home
  2. Microbiota 13 - October 2021
  3. Vaginal microbiota #13
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 13 - October 2021
  3. Vaginal microbiota #13
Gynecology

Vaginal microbiota #13

Bacterial vaginosis
Gynecology

By Pr. Markku Voutilainen
Turku University Faculty of Medicine; Turku University Hospital, Department of Gastroenterology, Turku, Finland

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

Sections

NL13_PR Vaginal microbiota

About this article

Created 25 October 2021
Updated 20 January 2022

Using recombinant endolysins to treat bacterial vaginosis

Landlinger C, Tisakova L, Oberbauer V. Engineered phage endolysin eliminates gardnerella biofilm without damaging beneficial bacteria in bacterial vaginosis ex vivo. Pathogens 2021; 10: 54.

A study has shown that by using recombinant endolysins of the type 1,4-beta- N-acetylmuramidase encoded on Gardnerella prophages it is possible to eliminate the bacterial biofilm responsible for bacterial vaginosis without damaging the beneficial bacteria of the vaginal microbiota. To this end, the authors generated several engineered endolysins, bacteriophage enzymes that lyse the bacterial wall, via domain shuffling. They compared their bactericidal activity on Gardnerella strains to that of wild-type endolysins. The bactericidal activity of the recombinant endolysins was 10 times that of any wild-type enzyme. When tested against a panel of 20 Gardnerella strains from 4 species (G. vaginalis, G. leopoldii, G. piotii and G. swidsinski), the most active endolysin, called PM-477, showed superior efficacy compared to the antibiotics tested (metronidazole, tinidazole, clindamycin). Furthermore, PM-477 had no effect on beneficial lactobacilli or other species of vaginal bacteria. According to the authors, PM-477 is highly selective for Gardnerella and kills strains of each of the four main species without affecting beneficial lactobacilli or other species typical of the vaginal microbiota. The effect of PM-477 was confirmed by microscopy in mixed cultures of Gardnerella and lactobacilli. To go further and analyze the efficacy of PM-477 in a physiological environment closely resembling the in vivo situation, the researchers treated vaginal swabs from 15 bacterial vaginosis patients and analyzed them by fluorescence in situ hybridization (FISH). They showed that in 13 of the 15 cases, PM-477 eradicated the Gardnerella bacterium and physically dissolved the biofilms without affecting the vaginal microbiota. According to the authors, endolysins are a promising therapeutic alternative to antibiotics for the treatment of bacterial vaginosis.

Tags
Bacterial Vaginosis Gynecology

en_view en_sources

    Focus
    Microbiota 13 - October 2021
    • Overview
      • Microbiota gut-brain axis in Irritable Bowel Syndrome
      • What is the impact of Covid-19 on the human microbiome?
    • Commented article
      • Faecal microbiota transplantation overcomes resistance to anti-PD-1 treatment in patients with melanoma
      • High-fibre diet mitigates maternal obesity-induced cognitive and social dysfunction in the offspring via gut-brain axis
    • Congress Review
      • DDW congress
      • Microbiota highlights from the 6th WCPGHAN 2021 Summit
    • Press Review
      • Gut microbiota #13
      • Vaginal microbiota #13
      • Skin microbiota #13
    Created 25 October 2021
    Updated 20 January 2022

    About this article

    To know more about this topic.

    Main topic

    Bacterial vaginosis

    Medical practice

    Gynecology

    Content type

    Press review
    Gut microbiota #13
    Skin microbiota #13
    Focus

    Microbiota 13 - October 2021

    Overview

    Microbiota gut-brain axis in Irritable Bowel Syndrome What is the impact of Covid-19 on the human microbiome?

    Commented article

    Faecal microbiota transplantation overcomes resistance to anti-PD-1 treatment in patients with melanoma High-fibre diet mitigates maternal obesity-induced cognitive and social dysfunction in the offspring via gut-brain axis

    Congress Review

    DDW congress Microbiota highlights from the 6th WCPGHAN 2021 Summit

    Press Review

    Gut microbiota #13 Vaginal microbiota #13 Skin microbiota #13
    Gynecology
    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article

    Vaginal microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more
    02.03.2021

    Cervicovaginal microbiota: a marker for persistent papillomavirus infection?

    Read the article

    Urinary tract infections

    Infections of the lower urogenital tract are extremely common amongst women: seven out of ten women will su...

    Find out more
    Actu PRO : Le microbiote vaginal prédictif du risque d’accouchement prématuré ?
    17.09.2019

    The vaginal microbiota as a predictor of the risk of premature delivery

    Read the article
    21.03.2022

    Endometriosis and Microbiota: what are the links ?

    Read the article
    25.11.2021

    Human microbiota: interconnected network that determines balance between health and illness?

    Read the article
    28.02.2022

    Endometrial microbiota: a new marker for IVF success?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    en_redirection

    en_you_are_about_to_leave

    • en_be_redirected
    • en_stay_on_biocodex

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo